Arnigen
Generic Name
Sacubitril/Valsartan
Manufacturer
Meditop Pharmaceuticals
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| arnigen 49 mg tablet | ৳ 85.00 | ৳ 850.00 |
Description
Overview of the medicine
Arnigen 49 mg Tablet is a combination medication containing Sacubitril and Valsartan, used to treat chronic heart failure with reduced ejection fraction. It works by enhancing the body's natural protective neurohormonal systems while blocking the harmful effects of overactive neurohormonal systems, leading to improved heart function and reduced symptoms.
Uses & Indications
Dosage
Adults
Initial dose: 49 mg Sacubitril/51 mg Valsartan orally twice daily. Double the dose every 2-4 weeks to target dose of 97 mg Sacubitril/103 mg Valsartan twice daily, as tolerated.
Elderly
No specific dose adjustment required based on age alone, but consider potential for decreased renal function.
Renal_impairment
For severe renal impairment (eGFR <30 mL/min/1.73 m²), consider lower starting dose (e.g., 24 mg Sacubitril/26 mg Valsartan twice daily).
How to Take
Administer orally twice daily, with or without food.
Mechanism of Action
Sacubitril is a neprilysin inhibitor that increases levels of natriuretic peptides, leading to vasodilation, natriuresis, and diuresis. Valsartan is an angiotensin II receptor blocker (ARB) that inhibits the deleterious effects of angiotensin II, such as vasoconstriction, aldosterone release, and cardiac remodeling. Together, they reduce cardiovascular mortality and heart failure hospitalizations.
Pharmacokinetics
Onset
Clinical effects seen within days to weeks; sustained benefit with chronic use.
Excretion
Primarily renal excretion (LBQ657) and fecal/biliary excretion (Valsartan).
Half life
LBQ657: 11.5 hours, Valsartan: 9.9 hours.
Absorption
Sacubitril is a prodrug, rapidly converted to active metabolite LBQ657. Valsartan is well absorbed. Peak plasma concentration for LBQ657 at 2 hours, Valsartan at 1.5 hours.
Metabolism
Sacubitril is metabolized by esterases to LBQ657. Valsartan is minimally metabolized.
Side Effects
Contraindications
- •Hypersensitivity to any component.
- •Concomitant use with ACE inhibitors (discontinue ACE inhibitor at least 36 hours prior to initiating Arnigen).
- •History of angioedema related to previous ACE inhibitor or ARB therapy.
- •Concomitant use of aliskiren in patients with diabetes or renal impairment.
- •Severe hepatic impairment.
Drug Interactions
NSAIDs
Increased risk of renal impairment, especially in elderly or volume-depleted patients. Monitor renal function.
Lithium
Increased serum lithium concentrations and toxicity. Monitor lithium levels.
ACE inhibitors
Increased risk of angioedema. Contraindicated.
Potassium-sparing diuretics, potassium supplements
Increased risk of hyperkalemia. Monitor potassium levels.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
Hypotension is the most likely symptom. Treatment is symptomatic and supportive. If recent ingestion, consider gastric lavage and activated charcoal.
Pregnancy & Lactation
Pregnancy: Discontinue immediately if pregnancy is detected due to fetal toxicity. Lactation: Not recommended. It is unknown if Sacubitril/Valsartan passes into breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date, check specific packaging for exact details.
Availability
Pharmacies, Hospitals
Approval Status
Approved by FDA (for original brand)
Patent Status
Generic versions available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
